PTC Therapeutics CLO sells 2,813 shares in plan
PTC THERAPEUTICS, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PTC THERAPEUTICS, INC. (PTCT) executive vice president and CLO Mark Elliott Boulding exercised stock options for 2,813 shares of common stock at an exercise price of $25.69 per share and then sold those 2,813 shares in two tranches at weighted average prices of $72.39 and $72.90 on August 17, 2026. Following the option exercise, he held 16,876 stock options under that award, which was granted on February 15, 2024 and vests over four years. These transactions were effected pursuant to a written Rule 10b5-1 plan adopted on September 10, 2025.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F4 | 2,813 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 2,813 | $25.69 | $72K |
| Sale | Common Stock F1, F2 | 1,844 | $72.39 | $133K |
| Sale | Common Stock F1, F3 | 969 | $72.90 | $71K |
Footnotes (4)
- F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
- F2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $71.72 to $72.67 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $72.73 to $73.02 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4. This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.
Key Figures
Key Terms
Rule 10b5-1 plan regulatory
Stock Option (Right to Buy) financial
weighted average price financial
vests over four years financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did PTCT executive Mark Elliott Boulding report on this Form 4?
At what prices did the PTCT insider sell common stock on August 17, 2026?
What was the stock option exercise price reported by the PTCT insider?
How many PTCT stock options does Mark Elliott Boulding hold after the reported transactions?
Were the August 17, 2026 PTCT insider transactions under a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.